The PEA3/E1AF/ETV4 gene encodes an Ets-related transcription factor that is expressed in the epithelial cells of the mammary gland. Previous reports have shown that PEA3 can up-regulate promoter activities of many genes associated with tumorigenesis. A significant fraction of those encode matrix metalloproteinases (MMP genes) required for degradation of the extracellular matrix. To better obtain a molecular characterization of PEA3 expression in sporadic breast cancer, we quantified PEA3 mRNA by means of real-time reverse transcriptase±polymerase chain reaction assay in a large series of human primary breast tumors. PEA3 expression showed wide variations in tumor tissues, being under-expressed in 30 of 130 (23.1%) and over-expressed in 18 of 130 (13.8%) compared with normal breast tissues. High PEA3 mRNA levels correlated significantly with Scarff±Bloom±Richardson histopathological grade III (P 0.018) but not with poor prognosis, suggesting that PEA3 is a marker of tumor aggressiveness rather than a prognostic factor in human breast cancer. We also observed positive links between the expression of PEA3 and those of MKI67 and ERBB2 (P 0.034 and P 0.045, respectively) and an inverse relationship with ERa (P 0.0016). Our results do not support recent findings suggesting that PEA3 could be a tumor-suppressor gene that can act therapeutically in ERBB2 over-expressed tumors. Our results also suggest major roles of the MMP2, NRG1 and CGB genes (which encode type I gelatinase, heregulin and human chorionic gonadotropin b subunit, respectively) in the PEA3 pathway dysregulation observed in breast cancer. Taken together, the data confirm the role of the PEA3 gene in breast tumorigenesis, and suggest the existence of numerous other still unknown genes transactivated by the PEA3 transcription factor.
Introduction
PEA3 is the prototypical member of one major subgroup of the superfamily of Ets-related transcription factors which, at the present time, is composed of three members, PEA3 (also known as E1AF or ETV4) (1), ER81/ETV1 (2) and ERM/ ETV5 (3). These three transcription factors are 495% identical in the Ets-domain and 485% in the transactivation acidic domain (4) . PEA3, as well as ER81, ERM and the other Etsrelated transcription factors bind to related DNA sequence elements in the promoters of target genes where they act to regulate transcription (5) . Several candidate target genes of the PEA3 transcription factor have been reported based largely on the occurrence of Ets-binding sites in their upstream regulatory regions. A large proportion of these genes encode matrix proteases (MMP-2, -7, -9, -13, -14 and -19, UPA F F F ) and some of their inhibitors (TIMP-1 F F F ), whose dysregulated expression has been associated with the invasive potential of tumor cells (5EE10). PEA3 can also regulate the transcription of several other genes including Connexin 26 (11) and ERBB2 (12) . In this latter study, the authors suggest that PEA3 binds directly to a consensus motif on the ERBB2 promoter and down-regulates the promoter activity.
PEA3 expression is mainly regulated by two distinct Rasdependent mitogen activated protein kinase (MAPK) pathways (13) . These MAPK cascades could be activated by upstream molecules including receptor tyrosine kinase such as ERBB2 receptor (14) or growth factors such as heregulin (15) and hepatocyte growth factor (16) . It is noteworthy that the relationship between PEA3 and ERBB2 is unclear. Xing et al. (12) suggest that PEA3 is able to repress ERBB2 gene expression while other authors suggest that up-regulation of ERBB2, via activation of MAPK cascades, results in increased PEA3 transcriptional activity (14) . In consequence, the function of PEA3 (oncogene or tumor-suppressor gene) should be clarified before the use of new PEA3-based therapies. Indeed, a phase II study has already been started to evaluate the therapeutic efficiency and tumor-suppression mechanisms of PEA3 (17) .
A recent publication also suggested the involvement of epigenetic mechanisms (DNA methylation) in the regulation of PEA3 gene expression (18) . These authors have analyzed 10% of all mouse genes by transcription profiling from conditional DNMT1-deficient primary mouse fibroblasts to identify genes induced by hypomethylation. These authors identified PEA3 gene as a major gene up-regulated by DNA hypomethylation via DNMT1 under-expression in the mouse cells.
The role of PEA3 in human breast cancer is poorly documented, and even less is known about the clinical significance of PEA3 expression in this setting (19, 20) . The few available data on PEA3 expression in breast cancer have been obtained using breast cancer cell lines (21) and mouse mammary tumors (22, 23) . Kaya et al. (24) showed that transfection of the noninvasive human breast cancer cell line MCF-7 with PEA3 gene results in induction of invasive and motile activities, accompanied by an up-regulation of MMP9. PEA3 is over-expressed in mammary tumors of MMTV-ERBB2 transgenic mice (22) . Expression of a dominant-negative PEA3 transgene in mammary epithelial cells of MMTV-ERBB2 transgenic mice dramatically delayed the onset of mammary tumors and reduced the number and size of such tumors in individual mice (20) . Taken together, these findings suggest a role of this transcription factor in breast cancer.
Only two clinical studies of women series with breast tumors examined the possible association between PEA3 expression and classical clinical and pathological parameters, including patient outcome (25, 26) . Benz et al. (25) examined PEA3 expression by in situ hybridization in a series of 74 human breast tumors without outcome. This study revealed that (i) PEA3 is over-expressed (42-fold) in the epithelial compartment of 76% of these breast tumors, (ii) PEA3 and ERBB2 are coordinately up-regulated, (iii) PEA3 over-expression does not correlate with nuclear grade, estrogen receptor a and S-phase fraction, and does not result from amplification of the PEA3 gene located in 17q22. The second study, realized at the protein level by immunohistochemistry, suggested that PEA3-positive status detected in 42% of 89 patients could be a factor of good prognostic significance (26) .
PEA3 is supposed to play an important role in breast cancer invasiveness/metastasis through transcription of numerous metastasis-related genes. However, no data are available on the expression pattern of both PEA3 gene and genes involved in the PEA3 signaling network in a series of human breast tumors.
Here, using real-time quantitative reverse transcriptaseEE polymerase chain reaction (RTEEPCR) assay, we quantified PEA3 mRNA expression in a series of 130 patients with unilateral invasive primary breast tumors and known long-term outcome. We then sought links between the PEA3 mRNA expression pattern and classical clinical, pathological and molecular parameters, including patient outcome.
We also examined the possible relationship between the expression of PEA3 and those of genes coding for (i) molecules putatively involved in upstream steps of PEA3 pathways including growth factors (EGF, AREG, EREG, NRG1, NRG2, NRG3, HGF) and their receptors (ERBB1, ERBB2, ERBB3, ERBB4), (ii) molecules putatively involved in downstream steps of PEA3 pathways including various matrix proteases (UPA, PLAT, MMP2, MMP7, MMP9, MMP14), their inhibitors (PAI1, PAI2, TIMP1, TIMP2, TIMP3, TIMP4) and the genes GJB2 (Connexin 26) and PLAUR (UPA receptor) and (iii) DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) as well as genes (GRO1, JUNB) highly co-up-regulated with PEA3 gene by DNA hypomethylation in conditional DNMT1-deficient primary mouse fibroblasts (18) .
Materials and methods

Patients and samples
We analyzed tissue from primary breast tumors excised from 130 women treated at the Centre Ren e Huguenin from 1977 to 1989. Adjacent sections were stained with hematoxylin and eosin to determine histologically the proportion of tumor cells in each sample. A tumor sample was considered suitable for this study if the proportion of tumor cells was 460%. Immediately following surgery the tumor samples were stored in liquid nitrogen until RNA extraction.
The patients (mean age 58.2 years, range 34EE91) met the following criteria: primary unilateral non-metastatic breast carcinoma on which complete clinical, histological and biological data were available; and no radiotherapy or chemotherapy before surgery. The histological type of each tumor, and the number of positive axillary nodes, were established at the time of surgery. The malignancy of infiltrating carcinomas was scored according to Bloom and Richardson's histoprognostic system. Estrogen receptor alpha (ERa) status was determined by real-time quantitative RTEEPCR assay (27) . The main classical prognostic factors of this breast tumors series have been reported previously (27) .
The median follow-up was 8.1 years (range 1.0EE15.9). Forty-seven patients relapsed (the distribution of first relapse events was as follows: 13 local and/or regional recurrences, 30 metastases, and four of both).
We also analyzed eight breast tumor cell lines obtained from the American Tissue Type Culture Collection (SK-BR-3, T-47D, BT-20, HBL-100, ZR-75-1, MDA-231, MDA-361 and MCF7).
Specimens of adjacent normal breast tissue from five of the breast cancer patients, and normal breast tissue from four women undergoing cosmetic breast surgery, were used as sources of normal RNA.
Real-time RTEEPCR Theoretical basis. Quantitative values are obtained from the cycle number (Ct value) at which the increase in fluorescent signal associated with an exponential growth of PCR products starts to be detected by the laser detector of the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA) using the PE Biosystems (Foster City, CA) analysis software according to the manufacturer's manuals.
The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of the gene coding for the TATA box-binding protein (TBP) (a component of the DNA-binding protein complex TFIID) as the endogenous RNA control, and each sample was normalized on the basis of its TBP content. The relative target gene expression level was also normalized to a calibrator, or 1Â sample, consisting of a pool of normal breast tissue specimens (quantification of PEA3 gene) or of the breast tumor tissue sample among the tested series which contained the smallest amount of target gene mRNA (quantification of other target genes).
Final results, expressed as N-fold differences in target gene expression relative to the TBP gene and the calibrator, termed`N PEA3 ', were determined as follows:
where DCt values of the sample and calibrator are determined by subtracting the Ct value of the target gene from the Ct value of the TBP gene.
Primers and PCR consumables. Primers for the TBP and target genes were chosen with the assistance of the computer programs Oligo 5.0 (National Biosciences, Plymouth, MN). We conducted BLASTN searches against dbEST, htgs and nr (the non-redundant set of the GenBank, EMBL and DDBJ database sequences) to confirm the total gene specificity of the nucleotide sequences chosen for the primers, and the absence of DNA polymorphisms. The primer pairs for PEA3 were selected to be unique when compared with the sequences of the closely related ER81/ETV1 and ERM/ETV5 genes. The nucleotide sequences of the primers used for PCR amplification of PEA3, TBP, MKI67 and other target genes are reported in Table I . To avoid amplification of contaminating genomic DNA, one of the two primers was placed in a different exon. For example, the upper primer of TBP was placed at the junction between exons 5 and 6, whereas the lower primer was placed in exon 6. Agarose gel electrophoresis allowed us to verify the specificity of PCR amplicons. Moreover, for each primer pair, we did no-template control and noreverse transcriptase control (RT negatively) assays, which produced negligible signal detection (usually 440 Ct in value), suggesting that primerEEdimer formation and genomic DNA contamination effects were negligible.
RNA extraction. Total RNA was extracted from breast specimens by using the acidEEphenol guanidium method. The quality of the RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under ultraviolet light.
cDNA synthesis. RNA was reverse transcribed in a final volume of 20 ml containing 1Â RT buffer (500 mM each dNTP, 3 mM MgCl 2 , 75 mM KCl, 50 mM TrisEEHCl pH 8.3), 20 U RNasin Ribonuclease inhibitor (Promega, Madison, WI), 10 mM dithiothreitol, 100 U Superscript II RNase H-reverse transcriptase (Gibco BRL, Gaithersburg, MD), 1.5 mM random hexamers (Pharmacia, Uppsala, Sweden) and 1 mg of total RNA. The samples were incubated at 20 C for 10 min and 42 C for 30 min, and reverse transcriptase was inactivated by heating at 99 C for 5 min and cooling at 5 C for 5 min.
PCR amplification. All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). PCR was performed using the SYBR Green PCR Core Reagents kit (Perkin-Elmer I.Bi eche et al.
Applied Biosystems). The thermal cycling conditions comprised an initial denaturation step at 95 C for 10 min and 50 cycles at 95 C for 15 s and 65 C for 1 min.
Statistical analysis
Relapse-free survival was determined as the interval between diagnosis and detection of the first relapse (local and/or regional recurrences, and/or metastases). Clinical and pathological parameters were compared using the 1 2 test. Spearman rank correlation test was used to study the association between continuous variables. Survival distributions were estimated by the KaplanEEMeier method (28) , and the significance of differences between survival rates was ascertained using the log-rank test (29) .
Results
PEA3 mRNA expression in normal breast tissues
To determine the cut-off point for altered PEA3 expression in breast cancer tissue, the N PEA3 value, calculated as described in the Materials and methods, was determined for nine normal breast The N PEA3 values (calculated as described in Materials and methods) were based on the amount of the PEA3 messenger relative to the TBP endogenous control to normalize the amount and quality of total RNA. TBP expression remains stable between the normal breast tissue samples and the breast tumor samples when it is normalized to a second endogenous RNA control, the RPLP0 gene (also known as 36B4), coding for the human acidic ribosomal phosphoprotein P0. In consequence, we obtained the same results concerning PEA3 gene expression in our breast tumor series when its expression is normalized to this second endogenous RNA control (RPLP0 gene).
Relationship between PEA3 mRNA levels and clinical and pathological parameters
We sought links between PEA3 mRNA expression status and standard clinical and pathological factors in breast cancer (Table II) . Links (or trends) were found between PEA3 gene status and ScarffEEBloomEERichardson (SBR) histopathological grade status (P 0.018) and lymph node status (P 0.075).
Patients with tumors over-expressing and/or under-expressing PEA3 did not relapse more frequently (Table II) and did not have significantly shorter relapse-free survival after surgery compared with patients with tumors normally expressing PEA3 (log-rank test, data not shown).
Relationship between PEA3 mRNA levels and molecular parameters The 130 tumors studied here for PEA3 mRNA expression had been tested previously for ERa, ERb and ERBB2 mRNA expression (Table III) (27, 30) . We observed a negative relationship between PEA3 and ERa mRNA levels (r À0.277, P 0.0016) and a positive relationship between PEA3 and ERBB2 mRNA levels (r 0.175, P 0.045). No link was observed between PEA3 and ERb mRNA levels.
Histoprognostic grade is a combination of three criteria: tubular differentiation, nuclear polymorphism and mitotic index. This latter component of the histoprognostic grade (mitotic index) was further explored in testing the relationship between the mRNA levels of PEA3 gene and a proliferationassociated gene, i.e. the MKI67 gene encoding the proliferationrelated Ki-67 antigen (32) , in the same series of 130 breast tumors (Table III) . We observed a significant positive correlation between PEA3 and MKI67 mRNA levels (r 0.184, P 0.034).
Relationship between PEA3 mRNA levels and that of various putative genes implicated in the PEA3 pathway dysregulation in breast cancer The possible relationship between the expression of PEA3 and of 30 candidate genes selected to be implicated in PEA3 pathway dysregulation by various studies, were analyzed in 11 PEA3-under-expressing and 11 PEA3-over-expressing breast tumors. These genes encode various growth factors and their receptors (EGF, AREG, EREG, NRG1, NRG2, NRG3, ERBB1, ERBB2, ERBB3, ERBB4, HGF), extracellular matrix and cell-surface molecules (UPA, PLAT, MMP2, MMP7, MMP9, MMP14, PAI1, PAI2, TIMP1, TIMP2, TIMP3, TIMP4, GJB2, PLAUR), DNA methyltransferases (DNMT1, DNMT3A, DNMT3B), as well as genes putatively up-regulated by hypomethylation (GRO1, JUNB).
To correct for variations in the amounts of RNA, the mRNA levels of PEA3 and of these 30 genes were normalized using the TBP endogenous control gene, which is a non proliferationassociated gene. As the PEA3 gene expression is proliferation dependent, the PEA3 and the 30 genes were also normalized using the MKI67 gene. The possible relation between the 30 genes and ERa gene expression was also examined in the same subset of 22 tumors. The results of these analyses are summarized in Table IV. When TBP gene was used for normalization, we found numerous significant positive associations between PEA3 and target genes (Table IV, column PEA3/TBP). However, these associations were only retained for EREG, NRG1, NRG3, ERBB1, MMP2, MMP7 when mRNA levels were normalized using the MKI67 proliferation-associated gene (Table IV, column PEA3/MKI67).
Among these six genes, EREG, NRG3, ERBB1 and MMP7 also correlated negatively with ERa gene expression (Table IV, column ERa). The associations between PEA3 and these four genes could be expected, as PEA3 expression is also strongly negatively linked to ERa expression (Table III) . Finally, only NRG1 and MMP2 were associated to PEA3 gene independently to proliferation and ERa expression status. The positive correlations between the expression of PEA3 and these two genes, in a proliferation-and ERa-independent fashion, was confirmed on a larger series of 54 breast tumors, including tumors over-expressing, under-expressing and normally expressing PEA3 (data not shown).
This same series of 130 breast tumors had been tested previously for mRNA expression of various other genes known to be altered in breast cancer, i.e. BRCA2, MYC, CCND1, STMN1 (Stathmin), TERT, RB1, CGB, CGA, PS2, AR, PGR, CAV1, CXCR4, CXCR12 and CDH1 (E-cadherin) genes. We found a significant positive link, in a proliferation-and ERaindependent fashion, between PEA3 and only the CGB gene, Statistical analysis performed on the 130 breast tumor series yields r 0.175, P 0.045 (Table III) . 
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which encodes the human chorionic gonadotropin b subunit (r 0.662, P 0.0008) (Table IV) .
Discussion
To find out more about PEA3 mRNA expression in sporadic breast cancer, we quantified PEA3 gene expression by means of real-time quantitative RTEEPCR in a series of 130 unilateral invasive primary breast tumors. We observed both underexpression (23%) and over-expression (14%) of PEA3 mRNA compared with normal breast tissue.
Variations are therefore observed in terms of frequency of PEA3 over-expression between our study and the two clinical studies published previously (25, 26) . It is noteworthy that our study examined PEA3 mRNA expression by real-time quantitative RTEEPCR analysis (14% of PEA3 over-expression; 43-fold representing over-expressing) whereas Benz et al. (25) examined PEA3 mRNA expression by in situ hybridation (76% of PEA3 over-expression; 42-fold) and Kinoshita et al. (26) examined PEA3 protein status (42% of PEA3 immunoreactivity-positive). In situ hybridation and immunohistochemistry assess specimens on an individual cell basis but have relatively little inter-laboratory standardization and are not accurate enough to quantify the full range of gene alterations. In consequence, further studies, using the same technical conditions, are necessary to determine the accurate frequency of PEA3 alteration in breast cancer.
In our study, significant links were observed between high PEA3 mRNA levels and SBR histopathological grade III, high MKI67 and ERBB2 mRNA levels and low ERa mRNA levels. High PEA3 mRNA levels were not associated with a poor prognosis, suggesting that PEA3 is a marker of tumor aggressiveness rather than a prognostic factor in human breast cancer. Formally, these observations are consistent with a model in which PEA3 exerts a positive effect on proliferation of breast tumor cell. Such a model is difficult to reconcile with the genetic evidence that PEA3 is a tumor-suppressor gene whose over-expression should inhibit breast tumorigenesis in repressing ERBB2 gene expression (12) . In this regard, our data are in agreement with those reported by Benz et al. (25) , which also showed a coordinately up-regulation between PEA3 and ERBB2 in breast cancer, suggesting that PEA3 has rather a role of an oncogene. Taken together, these findings coupled with previous observations demonstrating increased PEA3 transcript levels in mouse metastatic mammary adenocarcinomas (22) as well as in mammary tumors of MMTV-neu transgenic mice (23) suggest that the use of PEA3 as a therapeutic agent may not be appropriate in breast cancer. Our data, in agreement with those of Shepherd et al. (23) rather support the use of therapeutic agents that inhibit the expression or activity of PEA3 in the treatment of breast cancer.
With respect to PEA3 expression in cell lines, our results are in total agreement with those reported recently by Baert et al. (21) , who analyzed the PEA3 expression pattern in a large series of human breast cell lines by means of northern blotting. For example, the highest PEA3 expression levels observed by Baert and ourselves were in cell lines BT-20 and MDA-231.
We also studied the possible relationship between the expression of PEA3 gene and that of various candidate genes involved in the PEA3 pathway dysregulations observed in breast cancer. Among the 30 candidate genes tested, only the genes NRG1 and MMP2 were associated to PEA3 gene independently of proliferation and ERa expression status. It is noteworthy that the positive links observed between PEA3 expression and two well known genes transactivated by PEA3 transcription factor, i.e. MMP2 and NRG1, suggests a link between PEA3 mRNA level and PEA3 protein activity. We also identified an additional gene (CGB gene) linked to PEA3 among 16 genes known to be dysregulated in breast tumors, but not known to be transactivated by the PEA3 transcription factor.
Several results of this study do not confirm those reported in the literature or relationships hypothesized by ourselves. (i) We did not find any association in our breast tumor series between PEA3 gene and the genes UPA, GJB2 (coding for Connexin 26) or TIMP1, which reveal several PEA3 sites localized within their promoters (6, 8, 11) . (ii) We did not observe a link between the expressions of PEA3 and HGF (hepatocyte growth factor) as observed in vitro in oral squamous cell carcinoma cell (16) . (iii) Our data did not suggest that PEA3 gene is epigenetically regulated by DNA methylation as observed in the in vitro model with conditional DNMT1-deficient primary mouse fibroblasts (18) . Indeed, we did not observe links (independent of proliferation) between PEA3 and neither DNA methyltransferase genes (DNMT1, 3A and 3B) nor GRO1 and JUNB, which are highly co-upregulated with PEA3 in DNMT1-deficient mouse cells.
Our results identified type I gelatinase (MMP2) as the major matrix metalloproteinase activated by PEA3 in breast tumors. Higashino et al. (9) showed previously, in transient expression assays, that PEA3 can activate MMP2 gene promoter. Expression of the chloramphenicol acetyltransferase reporter gene under the control of MMP2 promoter was increased 410-fold by co-transfection with a PEA3 expression vector.
Our results also identified NRG1 (heregulin) among six ErbB-specific ligands as a major growth factor, which upregulates PEA3. Our in vivo study confirms the recently reported activation of PEA3 transcription by heregulin in an ERBB2-over-expressing breast cell line, i.e. SKBR3 cell line (15) .
Finally, our results suggest the existence of an additional target gene of PEA3 transcription factor, which could be associated with breast tumorigenesis. Indeed, among 16 genes known to be dysregulated in breast tumors, we identified the CGB gene encoding the glycoprotein hormone b subunit as a major target gene of PEA3 transcription factor. We have shown previously that CGB over-expression is associated with malignant breast transformation (33) . It is noteworthy that Johnson and Jameson (34) have recently identified Ets2, another member of Ets-related transcription factors, as a new factor involved in cyclic AMP induction of the human CGB promoter in the JEG-3 placental cell line. It is possible that in breast tumors, PEA3 could bind to the same identified Etsbinding site that the Ets2 transcription factor binds to in the human CGB promoter.
Further studies (including cDNA microarray analysis) are necessary to identify the complete list of the PEA3-stimulated genes. In this regard, Howe et al. (35) recently suggested that the PEA3 factor might contribute to the up-regulation of COX-2 expression.
In conclusion, this study confirms the role of the PEA3 gene in breast tumorigenesis, and suggests that PEA3 is a marker of tumor aggressiveness rather than a prognostic factor in human breast cancer. Our results do not confirm that PEA3 is a tumor-suppressor gene that can act therapeutically in ERBB2 over-expressed tumors. Our results confirm the MMP2 gene and identify the NRG1 gene in the PEA3 pathway dysregulation observed in breast cancer. Finally, we hypothesize the existence of numerous other genes (such as CGB) transactivated by the PEA3 transcription factor in breast cancer.
